Nitric oxide provokes tumor necrosis factor-alpha expression in adult feline myocardium through a cGMP-dependent pathway

Circulation. 2000 Sep 12;102(11):1302-7. doi: 10.1161/01.cir.102.11.1302.

Abstract

Background: The mechanism(s) responsible for the persistent coexpression of tumor necrosis factor-alpha (TNF-alpha) and nitric oxide (NO) in the failing heart is unknown.

Methods and results: To determine whether NO was sufficient to provoke TNF-alpha biosynthesis, we examined the effects of an NO donor, S-nitroso-N-acetyl penicillamine (SNAP), in buffer-perfused Langendorff hearts. SNAP (1 micromol/L) treatment resulted in a time- and dose-dependent increase in myocardial TNF-alpha mRNA and protein biosynthesis in adult cat hearts. The effects of SNAP were completely abrogated by a NO quenching agent, 2-(4-carboxyphenyl)-4, 4,5,5-tetramethylimidazoline-1-oxyl 3-oxide (C-PTIO), and mimicked by sodium nitroprusside. Electrophoretic mobility shift assays demonstrated that SNAP treatment led to the rapid induction of nuclear factor kappa-beta (NF-kappaB) but not AP-1. The importance of the cGMP pathway in terms of mediating NO-induced TNF-alpha biosynthesis was shown by studies that demonstrated that 8-bromo-cGMP mimicked the effects of SNAP and that the effects of SNAP could be completely abrogated using a cGMP antagonist, 1H-(1,2, 4)oxadiazolo(4,3-a)quinoxalin-1-one (ODQ), or protein kinase G antagonist (Rp-8-Br-cGMPS). SNAP and 8-Br-cGMP were both sufficient to lead to the site-specific phosphorylation (serine 32) and degradation of IkappaBalpha in isolated cardiac myocytes. Finally, protein kinase G was sufficient to directly phosphorylate IkappaBalpha on serine 32, a critical step in the activation of NF-kappaB.

Conclusions: These studies show that NO provokes TNF-alpha biosynthesis through a cGMP-dependent pathway, which suggests that the coincident expression of TNF-alpha and NO may foster self-sustaining positive autocrine/paracrine feedback inflammatory circuits within the failing heart.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Benzoates / pharmacology
  • Cats
  • Cyclic GMP / analogs & derivatives*
  • Cyclic GMP / antagonists & inhibitors
  • Cyclic GMP / pharmacology
  • Cyclic GMP / physiology*
  • Cyclic GMP-Dependent Protein Kinases
  • DNA-Binding Proteins / metabolism
  • Electrophoresis / methods
  • I-kappa B Proteins*
  • Imidazoles / pharmacology
  • In Vitro Techniques
  • Myocardium / metabolism*
  • NF-KappaB Inhibitor alpha
  • NF-kappa B / biosynthesis
  • Nitric Oxide / metabolism*
  • Nitric Oxide Donors / pharmacology
  • Nitroprusside / pharmacology
  • Oxadiazoles / pharmacology
  • Penicillamine / analogs & derivatives*
  • Penicillamine / pharmacology
  • Phosphorylation
  • Protein Kinases / metabolism
  • Quinoxalines / pharmacology
  • RNA, Messenger / metabolism
  • Thionucleotides / pharmacology
  • Tumor Necrosis Factor-alpha / biosynthesis*

Substances

  • 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one
  • Benzoates
  • DNA-Binding Proteins
  • I-kappa B Proteins
  • Imidazoles
  • NF-kappa B
  • Nitric Oxide Donors
  • Oxadiazoles
  • Quinoxalines
  • RNA, Messenger
  • S-nitro-N-acetylpenicillamine
  • Thionucleotides
  • Tumor Necrosis Factor-alpha
  • NF-KappaB Inhibitor alpha
  • 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole
  • 8-bromoguanosino-3',5'-cyclic monophosphorothioate
  • Nitroprusside
  • 8-bromocyclic GMP
  • Nitric Oxide
  • Protein Kinases
  • Cyclic GMP-Dependent Protein Kinases
  • Penicillamine
  • Cyclic GMP